We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Gilead Sciences (GILD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GILD and the rest of the Medical group's stocks.
Gilead Sciences is a member of the Medical sector. This group includes 758 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 14.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, GILD has returned 5.51% so far this year. Meanwhile, the Medical sector has returned an average of 5.14% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, this group has lost an average of 2.42% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Gilead Sciences (GILD - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GILD and the rest of the Medical group's stocks.
Gilead Sciences is a member of the Medical sector. This group includes 758 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GILD is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 14.09% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, GILD has returned 5.51% so far this year. Meanwhile, the Medical sector has returned an average of 5.14% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.
To break things down more, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 280 individual companies and currently sits at #103 in the Zacks Industry Rank. On average, this group has lost an average of 2.42% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.